

Table S2. Summary of coverage in targeted next generation sequencing assay (discovery)

Patient ID	Lesion type	Total Reads	Reads on Target	Mean coverage	Uniformity*	% of mutated positions with coverage >100X
IPP-01	Carcinoma	222,406	92.74%	1089	57.35%	83.8%
	adj-IPMN	206,501	97.49%	1057	41.96%	
	dist-IPMN	94,270	94.41%	472	62.56%	
	Duod	171,212	95.30%	855	53.94%	
IPP-02	Carcinoma	130,774	93.16%	703	83.40%	100.0%
	adj-IPMN	196,316	96.10%	1059	63.32%	
	dist-IPMN	47,480	80.82%	209	63.69%	
	Spleen	168,688	90.00%	844	78.96%	
IPP-03	Carcinoma	76,482	94.74%	390	62.29%	100.0%
	adj-IPMN	89,336	93.31%	443	54.32%	
	Duod	243,579	93.92%	1267	63.23%	
IPP-04	Carcinoma	111,281	79.07%	486	68.75%	100.0%
	adj-IPMN	77,549	88.51%	373	71.00%	
	dist-IPMN	87,962	94.89%	449	66.20%	
	Duod	99,779	95.26%	521	69.12%	
IPP-05	Carcinoma	56,669	86.59%	250	41.84%	100.0%
	dist-IPMN	65,560	95.38%	327	46.42%	
	Duod	56,237	98.13%	311	79.61%	
IPP-06	Carcinoma	89,760	95.24%	465	64.23%	83.3%
	adj-IPMN	58,759	71.75%	226	59.19%	
	dist-IPMN	51,358	93.53%	259	55.76%	
	Duod	175,373	94.09%	907	68.00%	
IPP-07	Carcinoma	78,400	91.88%	387	54.63%	100.0%
	adj-IPMN	71,131	95.93%	361	52.86%	
	dist-IPMN	82,603	96.21%	429	55.28%	
	Duod	89,376	96.37%	477	72.30%	
IPP-08	Carcinoma	125,198	89.21%	615	60.11%	100.0%
	adj-IPMN	80,442	94.26%	411	57.78%	
	dist-IPMN	68,949	92.97%	364	74.37%	
	Duod	88,344	94.10%	489	64.04%	
IPP-09	Carcinoma	84,948	96.24%	426	40.25%	100.0%
	adj-IPMN	101,053	96.11%	523	62.55%	
	dist-IPMN	126,724	95.99%	654	62.80%	
	Duod	320,611	94.56%	1711	79.24%	
IPP-10	Carcinoma	113,291	94.35%	587	61.59%	100.0%
	adj-IPMN	223,030	95.12%	1212	76.02%	
	dist-IPMN	105,392	96.81%	628	86.85%	
	Duod	160,482	96.66%	816	47.80%	
IPP-11	Carcinoma	58,249	93.86%	305	78.45%	100.0%
	dist-IPMN	63,707	96.69%	339	60.02%	
	Duod	152,875	91.88%	772	59.55%	
IPP-12	Carcinoma	65,903	86.84%	312	59.40%	100.0%
	adj-IPMN	72,472	94.13%	391	72.37%	
	dist-IPMN	72,288	91.82%	370	69.02%	
	Spleen	64,691	90.39%	320	61.96%	
IPP-13	Carcinoma	91,421	95.17%	516	88.06%	100.0%
	adj-IPMN	23,947	95.02%	1118	46.00%	
	dist-IPMN	81,717	93.74%	452	76.18%	
	Duod	84,544	93.74%	435	68.65%	
IPP-14	Carcinoma	70,613	88.47%	329	56.26%	100.0%
	adj-IPMN	38,297	80.26%	1160	50.22%	
	dist-IPMN	76,858	96.54%	427	73.21%	
	Duod	90,570	91.78%	452	62.50%	
IPP-15	Carcinoma	89,465	90.28%	429	52.80%	100.0%
	adj-IPMN	70,528	94.01%	351	50.32%	
	dist-IPMN	119,832	92.49%	602	64.05%	
	Duod	220,161	95.46%	1154	66.46%	
IPP-16	Carcinoma	110,210	94.53%	566	64.78%	100.0%
	adj-IPMN	101,160	94.40%	523	65.48%	
	dist-IPMN	79,786	95.41%	424	72.11%	
IPP-17	Carcinoma	289,869	96.07%	1543	72.14%	100.0%
	adj-IPMN	70,248	96.17%	365	50.45%	
	dist-IPMN	76,550	90.84%	385	61.11%	
	Duod	223,647	92.93%	1116	54.97%	
IPP-18	Carcinoma	130,950	95.58%	691	70.63%	100.0%
	adj-IPMN	120,287	89.74%	559	48.73%	
	dist-IPMN	277,830	93.52%	1353	42.32%	
IPP-18	dist-IPMN	132,303	92.12%	683	59.05%	100.0%

	Spleen	64,301	95.41%	352	68.93%	
<i>IPP-19</i>	Carcinoma	114,641	94.69%	610	73.46%	
	adj-IPMN	80,497	92.97%	409	67.86%	87.5%
	Duod	102,175	92.91%	531	72.00%	
	Carcinoma	76,759	87.80%	377	65.33%	
<i>IPP-20</i>	adj-IPMN	99,751	95.06%	530	56.69%	100.0%
	dist-IPMN	209,897	97.42%	1192	84.13%	
	Duod	122,294	95.09%	648	59.88%	
	Carcinoma	54,904	82.41%	246	60.27%	
<i>IPP-21</i>	adj-IPMN	40,737	90.04%	205	67.72%	100.0%
	dist-IPMN	45,559	96.51%	241	67.04%	
	Duod	66,460	88.70%	308	48.64%	
	Carcinoma	98,574	92.79%	531	58.46%	
<i>IPP-22</i>	adj-IPMN	114,976	81.73%	540	58.93%	100.0%
	dist-IPMN	147,410	91.91%	751	69.73%	
	Spleen	109,558	97.24%	596	71.31%	
	Carcinoma	55,911	86.15%	280	43.87%	
<i>IPP-23</i>	adj-IPMN	122,924	84.87%	606	71.04%	86.6%
	dist-IPMN	171,845	96.82%	971	84.75%	
	Duod	90,840	90.52%	459	74.09%	
	Carcinoma	176,410	96.59%	945	72.35%	
<i>IPP-24</i>	adj-IPMN	121,856	90.78%	591	54.16%	100.0%
	Duod	173,120	92.09%	873	64.72%	
	Carcinoma	48,449	92.49%	246	70.34%	
<i>IPP-25</i>	adj-IPMN	116,500	92.07%	595	68.97%	100.0%
	dist-IPMN	40,815	57.73%	122	36.92%	
	Duod	223,647	92.93%	1116	54.97%	
	Carcinoma	36,298	82.28%	158	52.50%	
<i>IPP-26</i>	adj-IPMN	23,618	95.19%	1208	73.03%	100.0%
	dist-IPMN	49,424	96.18%	255	66.07%	
	Duod	99,807	88.64%	518	64.95%	
	Carcinoma	54,730	95.73%	293	77.59%	
<i>IPP-27</i>	adj-IPMN	54,724	93.34%	317	91.94%	100.0%
	dist-IPMN	54,147	92.77%	280	72.81%	
	Duod	236,338	95.21%	1382	92.87%	
	Carcinoma	57,769	95.92%	321	75.76%	
<i>IPP-28</i>	adj-IPMN	38,614	70.91%	152	62.29%	100.0%
	Duod	342,830	95.16%	1879	82.79%	
	Carcinoma	61,901	95.82%	321	58.38%	
<i>IPP-29</i>	adj-IPMN	136,178	96.21%	765	73.29%	94.4%
	dist-IPMN	189,371	96.72%	1016	71.81%	
	Spleen	61,182	88.22%	290	41.75%	
	Carcinoma	58,271	90.03%	291	69.88%	
<i>IPP-30</i>	adj-IPMN	39,218	87.18%	1349	74.20%	100.0%
	Duod	133,435	96.15%	746	87.12%	
	Carcinoma	21,776	90.53%	1064	60.08%	
<i>IPP-31</i>	adj-IPMN	46,120	91.85%	223	41.96%	100.0%
	dist-IPMN	33,666	96.30%	171	51.11%	
	Duod	180,133	93.70%	1016	84.45%	
	Carcinoma	93,339	93.21%	470	61.44%	
<i>IPP-32</i>	adj-IPMN	29,125	97.42%	1585	68.91%	100.0%
	Duod	45,589	96.71%	242	71.89%	
	Carcinoma	111,541	94.38%	569	67.60%	
<i>IPP-33</i>	adj-IPMN	227,421	95.06%	1175	57.74%	100.0%
	Duod	70,156	98.00%	373	74.58%	
	Carcinoma	39,639	98.11%	205	35.22%	
<i>IPP-34</i>	adj-IPMN	137,648	97.12%	709	51.99%	100.0%
	Duod	132,810	90.55%	667	61.31%	
	Carcinoma	54,137	69.53%	198	66.72%	
<i>IPP-35</i>	adj-IPMN	95,756	93.23%	697	91.13%	100.0%
	dist-IPMN	22,191	92.02%	1179	74.53%	
	Spleen	69,251	95.63%	365	74.36%	
	Carcinoma	55,274	77.91%	251	60.04%	
<i>IPP-36</i>	adj-IPMN	92,223	94.53%	506	77.44%	100.0%
	dist-IPMN	99,437	94.30%	601	91.86%	
	Duod	82,192	94.57%	447	80.92%	
	Carcinoma	34,934	96.61%	199	86.43%	
<i>IPP-37</i>	dist-IPMN	15,903	97.76%	1183	54.56%	75.0%
	Duod	70,476	88.76%	342	78.18%	
	Carcinoma	119,563	96.48%	1178	40.85%	
<i>IPP-38</i>	adj-IPMN	26,637	90.65%	1132	65.05%	100.0%
	dist-IPMN	57,323	90.38%	288	75.73%	

	Duod	97,410	96.04%	550	90.23%	
<i>IPP-39</i>	Carcinoma	257,545	95.20%	1442	57.51%	
	adj-IPMN	116,576	99.03%	1102	53.45%	93.3%
	dist-IPMN	52,801	97.19%	316	91.21%	
	Duod	455,547	94.63%	2518	59.52%	
<i>IPP-40</i>	Carcinoma	53,110	92.23%	299	89.90%	
	adj-IPMN	73,855	82.44%	367	87.35%	100.0%
	dist-IPMN	127,101	93.92%	748	89.79%	
	Stomache	61,997	97.28%	373	88.13%	
<i>IPP-41</i>	Carcinoma	127,042	97.09%	1510	62.58%	
	adj-IPMN	44,924	97.10%	265	89.36%	100.0%
	Duod	98,450	92.50%	540	87.97%	
<i>IPP-42</i>	Carcinoma	59,094	96.73%	334	88.78%	
	dist-IPMN	59,542	97.97%	367	92.00%	100.0%
	Duod	40,048	96.00%	247	91.95%	
<i>IPP-43</i>	Carcinoma	75,281	98.18%	402	50.81%	
	adj-IPMN	62,814	85.60%	322	88.82%	93.3%
	dist-IPMN	37,512	92.74%	1960	82.80%	
	Spleen	52,358	88.68%	270	86.16%	
<i>IPP-44</i>	Carcinoma	119,506	95.38%	1110	47.80%	
	adj-IPMN	72,193	97.05%	421	88.36%	100.0%
	dist-IPMN	104,232	97.30%	587	63.82%	
	Duod	163,913	95.76%	980	87.60%	
<i>IPP-45</i>	Carcinoma	95,049	93.19%	597	92.90%	
	adj-IPMN	74,608	91.56%	469	93.25%	100.0%
	Duod	100,394	93.01%	619	92.23%	
<i>IPP-46</i>	Carcinoma	121,293	65.53%	476	89.98%	
	adj-IPMN	97,298	95.38%	559	84.50%	100.0%
	dist-IPMN	116,144	87.94%	673	93.67%	
	Spleen	70,686	95.11%	436	91.22%	
<i>IPP-47</i>	Carcinoma	76,943	97.22%	427	66.15%	
	adj-IPMN	65,203	96.71%	326	47.94%	100.0%
	Duod	231,255	96.32%	1564	92.37%	
<i>IPP-48</i>	Carcinoma	157,529	95.47%	933	90.11%	
	adj-IPMN	147,641	97.11%	893	91.21%	100.0%
	dist-IPMN	183,223	96.38%	1116	91.21%	
	Duod	337,685	97.24%	2302	91.21%	
<i>IPP-49</i>	Carcinoma	106,538	89.02%	564	82.27%	
	adj-IPMN	60,945	95.16%	375	92.65%	100.0%
	dist-IPMN	70,117	96.06%	456	91.60%	
	Stomache	108,944	95.45%	732	94.39%	
<i>IPP-50</i>	Carcinoma	34,977	95.29%	1183	59.86%	
	adj-IPMN	137,083	95.77%	823	90.82%	100.0%
	dist-IPMN	47,108	93.52%	263	91.31%	
	Duod	82,557	75.00%	356	75.40%	
<i>IPP-51</i>	Carcinoma	119,668	87.62%	659	93.35%	
	adj-IPMN	161,931	91.99%	925	92.98%	100.0%
	Duod	104,521	94.39%	622	78.44%	
<i>IPP-52</i>	Carcinoma	129,992	89.98%	705	90.92%	
	adj-IPMN	93,635	86.24%	498	75.16%	100.0%
	dist-IPMN	237,919	91.70%	1434	92.42%	
	Duod	94,335	94.41%	613	90.76%	
<i>IPP-53</i>	Carcinoma	130,533	96.48%	835	92.63%	
	adj-IPMN	36,036	87.68%	1365	86.29%	100.0%
	Duod	55,280	95.35%	359	88.42%	
<i>IPP-54</i>	Carcinoma	121,955	93.91%	746	90.50%	
	adj-IPMN	69,268	95.42%	423	92.42%	100.0%
	dist-IPMN	61,675	96.31%	376	93.72%	
	Duod	147,640	95.61%	977	72.68%	
<i>IPP-55</i>	Carcinoma	123,418	95.81%	801	92.03%	
	adj-IPMN	189,430	83.18%	1044	88.46%	100.0%
	dist-IPMN	88,521	95.45%	532	88.13%	
	Duod	153,418	96.16%	981	85.34%	
<i>IPC-56</i>	Carcinoma	43,618	90.31%	204	54.72%	
	adj-IPMN	117,899	71.63%	453	64.97%	77.8%
	dist-IPMN	106,260	95.21%	581	86.43%	
	Spleen	89,921	81.73%	381	81.55%	
<i>IPC-01</i>	Carcinoma	33,244	95.60%	1694	59.25%	
	adj-IPMN	212,810	91.24%	1025	53.32%	100.0%
	dist-IPMN	193,175	94.42%	1009	74.27%	
	Duod	192,062	90.74%	946	59.92%	
<i>IPC-02</i>	Carcinoma	165,913	92.10%	817	58.56%	90.0%

	dist-IPMN	59,312	89.35%	281	53.91%	
	Duod	113,320	78.31%	485	65.59%	
<i>IPC-03</i>	Carcinoma	77,685	92.66%	373	48.98%	
	adj-IPMN	24,661	90.30%	214	53.13%	100.0%
	Duod	84,469	93.53%	429	64.80%	
<i>IPC-04</i>	Carcinoma	91,050	93.13%	527	90.75%	
	adj-IPMN	112,197	92.84%	544	52.35%	100.0%
	Duod	99,273	89.87%	478	57.31%	
<i>IPC-05</i>	Carcinoma	118,615	96.93%	664	89.63%	
	adj-IPMN	58,444	92.39%	296	62.03%	100.0%
	dist-IPMN	65,564	93.98%	359	74.27%	
	Duod	106,906	92.76%	559	72.96%	
<i>IPC-06</i>	Carcinoma	110,586	54.10%	1071	81.95%	
	adj-IPMN	129,960	90.05%	572	34.59%	100.0%
	dist-IPMN	116,428	90.32%	552	51.45%	
	Duod	140,623	92.30%	716	58.79%	
<i>IPC-07</i>	Carcinoma	197,381	94.13%	1139	82.69%	
	adj-IPMN	109,988	94.13%	597	71.05%	100.0%
	Duod	206,497	94.73%	1112	80.64%	
<i>IPC-08</i>	Carcinoma	120,659	95.07%	631	70.15%	
	adj-IPMN	110,587	93.29%	540	48.58%	100.0%
	Duod	129,478	94.18%	651	55.26%	
<i>IPC-09</i>	Carcinoma	146,227	96.47%	845	91.81%	
	adj-IPMN	90,812	95.54%	514	87.05%	91.7%
	dist-IPMN	66,807	95.05%	376	89.61%	
	Duod	355,084	96.52%	1979	89.51%	
<i>IPC-10</i>	Carcinoma	89,464	95.83%	456	41.44%	
	adj-IPMN	65,772	97.35%	376	84.27%	83.3%
	dist-IPMN	49,990	97.18%	286	86.37%	
	Duod	57,479	95.88%	335	86.65%	
<i>IPC-11</i>	Carcinoma	34,725	96.00%	247	92.46%	
	adj-IPMN	36,636	91.82%	205	94.32%	100.0%
	dist-IPMN	46,667	93.03%	220	93.17%	
	Duod	35,000	94.81%	281	86.51%	
<i>IPC-12</i>	Carcinoma	70,721	96.29%	407	86.49%	
	adj-IPMN	175,737	98.04%	1094	90.20%	100.0%
	dist-IPMN	153,829	98.31%	966	90.69%	
	Duod	60,135	97.10%	372	91.16%	
<i>IPC-13</i>	Carcinoma	123,418	95.81%	801	92.03%	
	adj-IPMN	189,430	83.18%	1044	88.46%	100.0%
	dist-IPMN	88,521	95.45%	532	88.13%	
	Duod	153,418	96.16%	981	85.34%	
<i>IPA-01</i>	Carcinoma	56,237	98.13%	311	79.61%	
	adj-IPMN	123,833	96.01%	621	48.59%	80.0%
	dist-IPMN	86,257	93.38%	375	46.80%	
	Duod	55,515	95.29%	268	46.36%	
<i>IPA-02</i>	Carcinoma	98,024	89.84%	467	52.99%	
	adj-IPMN	63,726	78.50%	266	51.91%	77.8%
	dist-IPMN	61,574	75.45%	423	49.51%	
	Duod	253,057	96.14%	1293	57.23%	
<i>IPA-03</i>	Carcinoma	50,465	88.64%	243	64.95%	
	adj-IPMN	66,247	93.39%	336	68.80%	88.9%
	dist-IPMN	43,272	97.21%	222	44.10%	
	Duod	101,918	95.46%	525	67.48%	
<i>IPA-04</i>	Carcinoma	42,164	93.02%	221	78.76%	
	adj-IPMN	77,786	90.16%	388	61.73%	100.0%
	Duod	44,531	92.69%	223	64.80%	
<i>IPA-05</i>	Carcinoma	26,893	85.19%	1164	49.97%	
	adj-IPMN	53,722	92.09%	262	59.87%	100.0%
	Duod	50,279	84.89%	223	55.82%	
<i>IPA-06</i>	Carcinoma	96,701	96.88%	532	74.44%	
	adj-IPMN	38,167	94.08%	202	81.72%	93.3%
	dist-IPMN	100,487	93.84%	258	81.08%	
	Duod	56,452	95.40%	309	72.82%	
<i>IPA-07</i>	Carcinoma	198,738	94.62%	1062	88.00%	
	adj-IPMN	97,785	96.58%	540	87.18%	100.0%
	dist-IPMN	118,283	98.41%	650	67.08%	
	Duod	85,209	96.39%	469	84.86%	
Averages		104,401	92%	629	71%	97.1%
STD		63900	6%	396	15%	6.3%

*Uniformity - percentage of base in the target genes that are at least covered within 0.2X of the mean coverage depth

Table S2. Summary of coverage in targeted next generation sequencing assay (validation)

Patient ID	Lesion type	Total Reads	Reads on Target	Mean coverage	Uniformity*	% of mutated positions with coverage >100X
IPP05	Carcinoma	186,810	74.25%	703.2	46.71%	91.7%
	IPMN	334,767	92.30%	1,622	57.85%	
IPP09	Carcinoma	619,245	93.62%	3,109	65.87%	90.0%
	IPMN	459,403	94.86%	2,290	86.70%	
IPP13	Carcinoma	1,215,842	94.86%	6,715	86.70%	100%
	IPMN	159,267	95.74%	768.8	60.43%	
IPP15	Carcinoma	186,452	93.47%	936.7	62.09%	93.8%
	IPMN	245,205	95.76%	1,278	51.49%	
IPP19	Carcinoma	311,751	96.07%	1,734	82.71%	100%
	IPMN	296,861	94.44%	1,564	64.90%	
IPP22	Carcinoma	296,131	96.19%	1,679	85.24%	100%
	IPMN	270,585	95.68%	1,475	82.17%	
IPP31	Carcinoma	178,099	91.49%	849.7	53.96%	100%
	IPMN	254,900	95.13%	1,274	43.61%	
IPP35	Carcinoma	489,863	86.16%	2,224	55.60%	91.7%
	IPMN	448,050	92.71%	2,937	93.25%	
IPP36	Carcinoma	252,044	94.98%	1,389	86.09%	100%
	IPMN	254,744	95.74%	1,376	81.74%	
IPP43	Carcinoma	596,418	96.63%	3,577	85.28%	100%
	IPMN	570,276	96.82%	3,441	88.18%	
IPP44	Carcinoma	679,199	97.14%	3,976	90.17%	100%
	IPMN	365,596	96.61%	2,156	91.11%	
IPP45	Carcinoma	338,193	97.66%	2,156	91.17%	100%
	IPMN	582,669	98.20%	3,576	89.83%	
IPP47	Carcinoma	199,689	97.12%	1,295	79.56%	100%
	IPMN	458,686	97.99%	3,121	90.95%	
IPP50	Carcinoma	173,746	97.62%	949.9	59.26%	100%
	IPMN	235,103	97.82%	1,527	92.26%	
IPP54	Carcinoma	376,168	97.06%	2,380	87.76%	100%
	IPMN	533,889	96.87%	3,431	77.06%	
IPP56	Carcinoma	216,877	92.00%	1,063	61.32%	100%
	IPMN	596,418	96.63%	3,577	85.28%	
Averages		386,967	94.68%	2,192	75.51%	97.95%
STD		213239	4.39%	1265	15.34%	3.61%

*Uniformity - percentage of base in the target genes that are at least covered within 0.2X of the mean coverage depth

